 NEW YORK, Dec. 18, 2020 PRNewswire -- BrainStorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing Phase 2 trial evaluating NurOwn MSC-NTF cells as... 